author-photo

Srihari Gopal

Janssen Pharmaceutica
Johnson & Johnson Pharmaceutical Research and Development

123

Papers

8213

Citations

Citation Trend

Filter By

Papers (123) Sort By

Journal Conference Others

Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.

2021 Neuropsychiatric Disease and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia.

2021 The International Journal of Neuropsychopharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.

2021 CNS Drugs
Show All
- Source
- Cite
- Save
Citations (8)
89. GENOME WIDE META-ANALYSIS OF SUICIDE BEHAVIORS

2021 European Neuropsychopharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

2021 Patient Preference and Adherence
Show All
- Source
- Cite
- Save
Citations (0)
Relationship Between the Short-Form 12 (SF-12) and Schizophrenia Symptom Rating Scales in a Randomized Controlled Clinical Trial of Paliperidone Palmitate 3 Monthly Formulation

2021 Biological Psychiatry
Show All
- Source
- Cite
- Save
Citations (0)
PND5 Relationship between the Short-Form 12 (SF-12) and Schizophrenia Symptom Rating Scales in a Randomized Controlled Clinical Trial of Paliperidone Palmitate 3 Monthly Formulation

2021 Value in Health
Show All
- Source
- Cite
- Save
Citations (0)
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.

2021 Comprehensive Psychiatry
Show All
- Source
- Cite
- Save
Citations (0)
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

2020 Neuropsychiatric Disease and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.

2020 Neuropsychiatric Disease and Treatment
Show All
- Source
- Cite
- Save
Citations (1)